FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2477-2490 December 8, 2005 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In the United States, renal cancer is the 7th leading malignant condition among men and the 12th among women, accounting for 2.6 percent of all cancers.¹ About 2 percent of cases of renal cancer are associated with inherited syndromes. In the United States, 36,160 new cases of renal cancer are predicted to occur in 2005, many of which are being discovered earlier because of the widespread availability of radiographic testing. Nevertheless, 12,660 deaths from the disease are predicted to occur in 2005.¹ Renal-cell carcinomas arise from the renal epithelium and account for about 85 percent of renal cancers. A quarter . . . [Full Text of this Article]

Overview

Tumor Types and Molecular Pathogenesis

Conventional or Clear-Cell Renal-Cell Carcinoma

Papillary Renal-Cell Carcinoma

Oncocytoma and Chromophobe Renal-Cell Carcinoma

Collecting-Duct Renal-Cell Carcinoma

Management of Sporadic and Hereditary Renal-Cell Carcinoma

Prognosis

Surgical Treatment

Radical Nephrectomy

Surgery for Metastatic Disease

Nephron-Sparing Partial Nephrectomy

Laparoscopic Nephrectomy

Percutaneous Ablative Approaches

Medical Treatment

Chemotherapy

Immunomodulatory Therapies

            Interferon Alfa

            Interleukin-2

Adjuvant Therapy

Evolving Therapies

Stem-Cell Transplantation

Tumor Vaccines

Target Antigens

Therapies Targeting VEGF and TGF- Pathways

            VEGF-Pathway Components as Molecular Targets

            TGF-–Pathway Components as Molecular Targets

            Other Approaches

Summary and Prospects for the Future

Source Information

From the Renal and Hematology–Oncology Sections, Departments of Medicine and Pathology, Boston University School of Medicine (H.T.C.); and the Department of Urology, Massachusetts General Hospital and Harvard Medical School (F.J.M.) — all in Boston.

Address reprint requests to Dr. Cohen at the Department of Medicine, Renal Section, Boston University School of Medicine, Evans Biomedical Research Center, 650 Albany St., Rm. X-535, Boston, MA 02118, or at htcohen@bu.edu.

Related Letters:

Renal-Cell Carcinoma
Doh L., Curtis A. E., Teh B. S., Vincenzi B., Santini D., Tonini G., Cohen H. T., McGovern F. J.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1095-1096, Mar 9, 2006. Correspondence

This article has been cited by other articles:

• Shablak, A., Hawkins, R. E., Rothwell, D. G., Elkord, E. (2009). T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective. Clin. Cancer Res. 15: 6503-6510 [Abstract] [Full Text]  
• Montero, A. J., Diaz-Montero, C. M., Millikan, R. E., Liu, J., Do, K.-A., Hodges, S., Jonasch, E., McIntyre, B. W., Hwu, P., Tannir, N. (2009). Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-{alpha}: association of pretreatment serum levels with survival. Ann Oncol 20: 1682-1687 [Abstract] [Full Text]  
• Yang, S., Ngo, V. C., Lew, G. B., Chong, L. W. V., Lee, S. S., Ong, W. J. R., Lam, W. L. I., Thng, C. H., Koong, H. N., Ong, H. S., Chung, A., Chow, P., Lee, J., Soo, K. C., Huynh, H. (2009). AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Molecular Cancer Therapeutics 8: 2537-2545 [Abstract] [Full Text]  
• Wiklund, F., Tretli, S., Choueiri, T. K., Signoretti, S., Fall, K., Adami, H.-O. (2009). Risk of Bilateral Renal Cell Cancer. JCO 27: 3737-3741 [Abstract] [Full Text]  
• Gustafsson, A., Martuszewska, D., Johansson, M., Ekman, C., Hafizi, S., Ljungberg, B., Dahlback, B. (2009). Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival. Clin. Cancer Res. 15: 4742-4749 [Abstract] [Full Text]  
• Morris, Z. S., McClatchey, A. I. (2009). Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc. Natl. Acad. Sci. USA 106: 9767-9772 [Abstract] [Full Text]  
• Liu, J., Ghanim, M., Xue, L., Brown, C. D., Iossifov, I., Angeletti, C., Hua, S., Negre, N., Ludwig, M., Stricker, T., Al-Ahmadie, H. A., Tretiakova, M., Camp, R. L., Perera-Alberto, M., Rimm, D. L., Xu, T., Rzhetsky, A., White, K. P. (2009). Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney Cancer. Science 323: 1218-1222 [Abstract] [Full Text]  
• Macher-Goeppinger, S., Aulmann, S., Tagscherer, K. E., Wagener, N., Haferkamp, A., Penzel, R., Brauckhoff, A., Hohenfellner, M., Sykora, J., Walczak, H., Teh, B. T., Autschbach, F., Herpel, E., Schirmacher, P., Roth, W. (2009). Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. Clin. Cancer Res. 15: 650-659 [Abstract] [Full Text]  
• Cheng, L., MacLennan, G. T., Zhang, S., Wang, M., Zhou, M., Tan, P.-H., Foster, S., Lopez-Beltran, A., Montironi, R. (2008). Evidence for Polyclonal Origin of Multifocal Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 14: 8087-8093 [Abstract] [Full Text]  
• Silverman, S. G., Israel, G. M., Herts, B. R., Richie, J. P. (2008). Management of the Incidental Renal Mass. Radiology 249: 16-31 [Abstract] [Full Text]  
• Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K.C., Rock, K. L., Wu, C.-L. (2008). Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas. Clin. Cancer Res. 14: 5579-5584 [Abstract] [Full Text]  
• Moore, S. C., Chow, W.-H., Schatzkin, A., Adams, K. F., Park, Y., Ballard-Barbash, R., Hollenbeck, A., Leitzmann, M. F. (2008). Physical Activity during Adulthood and Adolescence in Relation to Renal Cell Cancer. Am J Epidemiol 168: 149-157 [Abstract] [Full Text]  
• Signoretti, S., Bratslavsky, G., Waldman, F. M., Reuter, V. E., Haaga, J., Merino, M., Thomas, G. V., Pins, M. R., Libermann, T., Gillespie, J., Tomaszewski, J. E., Compton, C. C., Hruszkewycz, A., Linehan, W. M., Atkins, M. B. (2008). Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. Clin. Cancer Res. 14: 3699-3705 [Abstract] [Full Text]  
• Michaelson, M. D., Iliopoulos, O., McDermott, D. F., McGovern, F. J., Harisinghani, M. G., Oliva, E. (2008). Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma. NEJM 358: 2389-2396 [Full Text]  
• Dyer, R., DiSantis, D. J., McClennan, B. L. (2008). Simplified Imaging Approach for Evaluation of the Solid Renal Mass in Adults. Radiology 247: 331-343 [Abstract] [Full Text]  
• Hagemann, I.S., Lu, J., Lewis, J.S. Jr (2008). Basaloid Squamous Cell Carcinoma Arising of the Renal Pelvis. INT J SURG PATHOL 16: 199-201 [Abstract]  
• Hiles, J. J., Kolesar, J. M. (2008). Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65: 123-131 [Abstract] [Full Text]  
• Habib, S. L., Riley, D. J., Mahimainathan, L., Bhandari, B., Choudhury, G. G., Abboud, H. E. (2008). Tuberin regulates the DNA repair enzyme OGG1. Am. J. Physiol. Renal Physiol. 294: F281-F290 [Abstract] [Full Text]  
• Sourbier, C., Danilin, S., Lindner, V., Steger, J., Rothhut, S., Meyer, N., Jacqmin, D., Helwig, J.-J., Lang, H., Massfelder, T. (2007). Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy. Cancer Res. 67: 11668-11676 [Abstract] [Full Text]  
• Coetzee, E. J. (2007). Counterpoint: Oral Hypoglyemic Agents Should Be Used to Treat Diabetic Pregnant Women. Diabetes Care 30: 2980-2982 [Full Text]  
• Lin, S.-P., Bierhals, A. J., Lewis, J. S. Jr (2007). Best Cases from the AFIP: Metastatic Renal Cell Carcinoma. RadioGraphics 27: 1801-1807 [Full Text]  
• Motzer, R. J., Hudes, G. R., Curti, B. D., McDermott, D. F., Escudier, B. J., Negrier, S., Duclos, B., Moore, L., O'Toole, T., Boni, J. P., Dutcher, J. P. (2007). Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma. JCO 25: 3958-3964 [Abstract] [Full Text]  
• Agouni, A., Sourbier, C., Danilin, S., Rothhut, S., Lindner, V., Jacqmin, D., Helwig, J.-J., Lang, H., Massfelder, T. (2007). Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B. Carcinogenesis 28: 1893-1901 [Abstract] [Full Text]  
• Berndt, S. I., Carter, H. B., Schoenberg, M. P., Newschaffer, C. J. (2007). Disparities in Treatment and Outcome for Renal Cell Cancer Among Older Black and White Patients. JCO 25: 3589-3595 [Abstract] [Full Text]  
• Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., Mao, M., Bartz, S., Kaelin, W. G. Jr. (2007). Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations. Mol. Cell. Biol. 27: 5381-5392 [Abstract] [Full Text]  
• Prasad, S R, Narra, V R, Shah, R, Humphrey, P A, Jagirdar, J, Catena, J R, Dalrymple, N C, Siegel, C L (2007). Segmental disorders of the nephron: histopathological and imaging perspective. Br. J. Radiol. 80: 593-602 [Abstract] [Full Text]  
• Furge, K. A., Chen, J., Koeman, J., Swiatek, P., Dykema, K., Lucin, K., Kahnoski, R., Yang, X. J., Teh, B. T. (2007). Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma. Cancer Res. 67: 3171-3176 [Abstract] [Full Text]  
• Kleinrath, T., Gassner, C., Lackner, P., Thurnher, M., Ramoner, R. (2007). Interleukin-4 Promoter Polymorphisms: A Genetic Prognostic Factor for Survival in Metastatic Renal Cell Carcinoma. JCO 25: 845-851 [Abstract] [Full Text]  
• Chouhan, J. D, Zamarripa, D. E, Lai, P. H, Oramasionwu, C. U, Grabinski, J. L (2007). Sunitinib (Sutent(R)): A novel agent for the treatment of metastatic renal cell carcinoma. J Oncol Pharm Pract 13: 5-15 [Abstract]  
• Wu, M.-Y., Liaw, C.-C., Chen, Y.-C., Tian, Y.-C., Hsueh, S., Jenq, C.-C., Fang, J.-T., Yang, C.-W. (2007). A giant sarcomatoid renal cell carcinoma. Nephrol Dial Transplant 22: 952-953 [Full Text]  
• Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V.S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., Chidambaram, N., Jiang, J. X., Tang, S., Mahjoob, K., Justice, R., Pazdur, R. (2007). Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma. Clin. Cancer Res. 13: 1367-1373 [Abstract] [Full Text]  
• Kawamoto, S., Permpongkosol, S., Bluemke, D. A., Fishman, E. K., Solomon, S. B. (2007). Sequential Changes after Radiofrequency Ablation and Cryoablation of Renal Neoplasms: Role of CT and MR Imaging. RadioGraphics 27: 343-355 [Abstract] [Full Text]  
• McDermott, D. F. (2007). Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma. Clin. Cancer Res. 13: 716s-720s [Abstract] [Full Text]  
• Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., Bukowski, R. M., the TARGET Study Group, (2007). Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. NEJM 356: 125-134 [Abstract] [Full Text]  
• Tanaka, Y., Hirata, H., Chen, Z., Kikuno, N., Kawamoto, K., Majid, S., Tokizane, T., Urakami, S., Shiina, H., Nakajima, K., Dhir, R., Dahiya, R. (2007). Polymorphisms of Catechol-O-Methyltransferase in Men with Renal Cell Cancer. Cancer Epidemiol. Biomarkers Prev. 16: 92-97 [Abstract] [Full Text]  
• Evans, A. J., Russell, R. C., Roche, O., Burry, T. N., Fish, J. E., Chow, V. W. K., Kim, W. Y., Saravanan, A., Maynard, M. A., Gervais, M. L., Sufan, R. I., Roberts, A. M., Wilson, L. A., Betten, M., Vandewalle, C., Berx, G., Marsden, P. A., Irwin, M. S., Teh, B. T., Jewett, M. A. S., Ohh, M. (2007). VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. Mol. Cell. Biol. 27: 157-169 [Abstract] [Full Text]  
• Seliger, B., Fedorushchenko, A., Brenner, W., Ackermann, A., Atkins, D., Hanash, S., Lichtenfels, R. (2007). Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1]. Clin. Cancer Res. 13: 27-37 [Abstract] [Full Text]  
• Yao, M., Huang, Y., Shioi, K., Hattori, K., Murakami, T., Nakaigawa, N., Kishida, T., Nagashima, Y., Kubota, Y. (2007). Expression of Adipose Differentiation-Related Protein: A Predictor of Cancer-Specific Survival in Clear Cell Renal Carcinoma. Clin. Cancer Res. 13: 152-160 [Abstract] [Full Text]  
• Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., Pazdur, R. (2007). Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma. The Oncologist 12: 107-113 [Abstract] [Full Text]  
• Shioi, K.-i., Komiya, A., Hattori, K., Huang, Y., Sano, F., Murakami, T., Nakaigawa, N., Kishida, T., Kubota, Y., Nagashima, Y., Yao, M. (2006). Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients. Clin. Cancer Res. 12: 7339-7346 [Abstract] [Full Text]  
• Parton, M., Gore, M., Eisen, T. (2006). Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer. JCO 24: 5584-5592 [Abstract] [Full Text]  
• Iliopoulos, O. (2006). Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets. JCO 24: 5593-5600 [Abstract] [Full Text]  
• Pan, S. Y., DesMeules, M., Morrison, H., Wen, S. W., The Canadian Cancer Registries Epidemiology Resear, (2006). Obesity, High Energy Intake, Lack of Physical Activity, and the Risk of Kidney Cancer. Cancer Epidemiol. Biomarkers Prev. 15: 2453-2460 [Abstract] [Full Text]  
• Prasad, S. R., Humphrey, P. A., Catena, J. R., Narra, V. R., Srigley, J. R., Cortez, A. D., Dalrymple, N. C., Chintapalli, K. N. (2006). Common and Uncommon Histologic Subtypes of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation. RadioGraphics 26: 1795-1806 [Abstract] [Full Text]  
• Iliopoulos, O., Chan-Smutko, G., Gonzalez, R. G., Louis, D. N., Stone, J. R. (2006). Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the right hand and hypertension.. NEJM 355: 394-402 [Full Text]  
• Doh, L., Curtis, A. E., Teh, B. S., Vincenzi, B., Santini, D., Tonini, G., Cohen, H. T., McGovern, F. J. (2006). Renal-cell carcinoma.. NEJM 354: 1095-1096 [Full Text]